Lisdexamfetamine vs Methylphenidate
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
Lisdexamfetamine (Vyvanse) and methylphenidate (Ritalin, Concerta) represent the two major stimulant classes used for ADHD treatment: amphetamine-based and methylphenidate-based [1][2]. While both are first-line ADHD medications, they have different mechanisms of action and some patients respond better to one class than the other.
Methylphenidate has been used for ADHD since the 1960s and remains one of the most widely prescribed stimulants worldwide [1]. Lisdexamfetamine, approved in 2007, is a prodrug that converts to dextroamphetamine and was designed to provide smooth, long-lasting ADHD symptom control with lower abuse potential [2].
Approximately 70% of ADHD patients respond to stimulants, and if a patient does not respond to one class (amphetamine or methylphenidate), there is a good chance they will respond to the other — making it important to understand both options [3].
Lisdexamfetamine vs Methylphenidate: Side-by-side comparison
| Category | Lisdexamfetamine | Methylphenidate |
|---|---|---|
| Drug Class | Amphetamine prodrug (stimulant) | Methylphenidate (stimulant) |
| Generic Name | Lisdexamfetamine dimesylate | Methylphenidate HCl |
| Brand Name | Vyvanse | Ritalin, Concerta, Focalin |
| FDA Approved For | ADHD, binge eating disorder | ADHD, narcolepsy |
| How It Works | Prodrug → dextroamphetamine; increases DA and NE release | Blocks dopamine and norepinephrine reuptake |
| Duration of Action | Up to 13-14 hours | IR: 3-4 hours; ER: 8-12 hours |
| Dosage Forms | Capsules (10-70 mg), chewable | Tablets, capsules, ER tablets, patch, liquid |
| Typical Dose | 30-70 mg once daily | IR: 5-20 mg 2-3x daily; ER: 18-72 mg once daily |
| Common Side Effects | Decreased appetite, insomnia, dry mouth, irritability | Decreased appetite, insomnia, headache, anxiety |
| Abuse Potential | Lower (prodrug mechanism) | Moderate (especially IR formulations) |
| Cost (Generic) | $30-$80/month | $15-$40/month |
| DEA Schedule | Schedule II | Schedule II |
Efficacy: How well does each drug work?
Both medication classes are highly effective for ADHD, with effect sizes of 0.8-1.3 for symptom reduction — among the largest effect sizes in psychiatry [3][4]. Meta-analyses suggest amphetamines (including lisdexamfetamine) may have slightly larger effect sizes than methylphenidate in adults, while the difference in children is less clear [4].
Lisdexamfetamine provides up to 13-14 hours of symptom coverage with its prodrug design [2]. Methylphenidate formulations vary widely: immediate-release (3-4 hours), Ritalin LA (8 hours), Concerta (12 hours), and others [1].
Lisdexamfetamine is also FDA-approved for moderate-to-severe binge eating disorder, an indication methylphenidate does not have [2]. For patients with comorbid ADHD and BED, lisdexamfetamine has a unique advantage.
Side effects comparison
Both medication classes share stimulant side effects: decreased appetite, insomnia, headache, dry mouth, and increased heart rate/blood pressure [1][2]. However, there are subtle differences.
Methylphenidate may cause more anxiety and tics in some patients, while amphetamines (including lisdexamfetamine) may cause more euphoria and have higher abuse potential [1][2][3]. Lisdexamfetamine's prodrug mechanism mitigates the abuse concern to some extent [2].
Appetite suppression and weight loss tend to be similar with both classes at equivalent doses. Growth monitoring is recommended for both in children and adolescents [1][2].
Both classes are Schedule II controlled substances. Both carry FDA warnings about serious cardiovascular risks and potential for dependence [1][2]. Psychiatric adverse effects (psychosis, mania) are rare but possible with both.
Cost comparison
Generic methylphenidate (IR and ER formulations) is widely available at $15-$40 per month [5]. Generic lisdexamfetamine became available in 2023, costing $30-$80 per month [5]. Brand Concerta can cost $200-$400, and brand Vyvanse was $350+ before generic entry. Both are generally covered by insurance with varying copays.
Convenience and dosing
Lisdexamfetamine is taken once daily as a capsule (can be opened and dissolved in water) [2]. Methylphenidate formulations vary: IR requires 2-3 daily doses, while long-acting forms (Concerta, Ritalin LA) are once-daily [1]. Lisdexamfetamine offers the simplest regimen with the longest consistent coverage. Methylphenidate offers more formulation variety (tablets, capsules, patches, liquid) for patients with specific needs.
Which is right for you?
Neither stimulant class is universally superior — individual response guides selection [3][4]. Many clinicians start with methylphenidate (especially in children) due to its longer track record and lower cost, then switch to lisdexamfetamine or other amphetamines if response is inadequate.
Lisdexamfetamine may be preferred for patients needing very long coverage (13+ hours), those with abuse risk concerns, patients with comorbid binge eating disorder, and those who prefer once-daily simplicity [2].
Methylphenidate may be preferred when cost is a priority, when formulation flexibility is needed (patch, liquid), or when a patient does not respond to amphetamines [1][3].
This information is for educational purposes only. ADHD medication selection should be guided by your healthcare provider.
Frequently asked questions
References
- [Regulatory] Methylphenidate HCl (Concerta) prescribing information. Janssen. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021121s042lbl.pdf Accessed 2025-06-15.
- [Regulatory] Vyvanse (lisdexamfetamine dimesylate) prescribing information. Takeda. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021977s045,208510s007lbl.pdf Accessed 2025-06-15.
- [Regulatory] Cortese S, et al. Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. https://doi.org/10.1016/S2215-0366(18)30269-4 Accessed 2025-06-15.
- [Regulatory] Faraone SV. Using meta-analysis to compare the efficacy of medications for ADHD in youths. P T. 2009;34(12):678-694. https://pubmed.ncbi.nlm.nih.gov/20140143/ Accessed 2025-06-15.
- [Observational] GoodRx price comparison: lisdexamfetamine and methylphenidate. https://www.goodrx.com Accessed 2025-06-15.
Written and fact-checked by PrescriptionDrugs.org Editorial Team
Last updated: